Table 2.
Summary of ADC drugs approved by the FDA as of march 2024
| Drug | Maker | Target | Toxin | Linker | Indications | DAR | Approval Date | Effect |
|---|---|---|---|---|---|---|---|---|
| Mylotarg | Pfizer | CD33 | Calicheamicin | hydrazone | AML | 2 ~ 3 | 2000 | Only Chemotherapy mPFS: 9.5 months, Combined Chemotherapy mPFS: 17.3 months |
| Adcetris | Seagen | CD30 | MMAE | dipeptide | Hodgkin’s lymphoma | 4 | 2011 | 2-year PFS at 82.1%, Control at 7.2%, progession risk lowered by 34% |
| Kadcyla | Roche | HER2 | DM1 | organic sulphide | Early-stage and metastatic HER2+ breast cancer | 3.5 | 2013 | mPFS at 6.2 months, control at 3.3 months; ORR at 31.3% vs. 8.6% |
| Besponsa | Pfizer | CD22 | Calicheamicin | hydrazone | BCP-ALL | 5 ~ 7 | 2017 | CR at 80.%, Chemotherapy at 29.4%, mOS at 7.7 vs. 6.7 months |
| Lumoxiti | AstraZeneca | CD22 | PE38 | mc-VC-PABC | HCL | / | 2018 | ORR at 75%, CR at 36% |
| Polivy | Roche | CD79β | MMAE | dipeptide | LBCB | 3.5 | 2019 | CR at 40, control at 19%, mOS at 12.4 vs. 4.7 months |
| Enhertu | Daiichi Sankyo | HER2 | Dxd | Boc-Gly-Gly-Phe-Gly-OH | Breast/Stomach Cancer | 8 | 2019 | mOS at 12.5 months, Chemotherapy at 8.4 mpnths, ORR at 41% vs. 11% |
| Padcev | Seagen | Nectin-4 | MMAE | mc-VC-PABC | Bladder Cancer | 4 | 2019 | mOS at 12.9 months, Chemotherapy at 9.0 months |
| Trodelvy | Immunomdecis | TROP-2 | SN38 | CL2A | TNBC | 8 | 2020 | mPFS at 4.8 months, Chemotherapy at 1.7 months; mOS at 11.8 vs. 6.9 |
| Belenrep | GSK | BCMA | MMAF | Not Cleavable | multiple myeloma | 4 | 2020 | ORR at 32%, mPFS at 11 months, mOS at 11.8 vs. 6.9 |
| Akalux | Rakuten Medical | EGFR | IRDye700DX | N/A | Head and Neck Cancer | / | 2020 | ORR at 43.3%, CR at 13.3% |
| Zynlonta | ADC Therapeutics | CD19 | PBD | dipeptide | LBCB | 2.3 | 2021 | ORR at 48.3%, CR at 24.8% (Including failed CAR-T patients) |
| RC48 -ADC | RemeGen | HER2 | MMAE | mc-VA-PABC | Stomach cancer | 3.5 | 2021 | ORR at 40%, mPFS at 6.3 months |
| Tivdak | Genmab/Seagen | TF | MMAE | Enzyme-cleaved | Cervical cancer | 4 | 2021 | OOR at 24%, DOR at 8.3 months |
| Elahere | ImmunoGen | FRα | DM4 | Non-cleavable | ovarian cancer | 3.4 | 2022 | ORR 42.3%, mPFS 5.62 months, OS 16.5 months |
| Trastuzumab Deruxtecan | Daiichi Sankyo and AstraZeneca | HER2 | Deruxtecan | Chemical cleavable | Breast cancer | 8 | 2022 | ORR 43.2%, DCR 79.5%, mPFS 5.6 months, 12.8 months |
mPFS Median Progression-Free Survival, ORR Objective Response Rate, CR Complete Response, DCR Disease Control Rate, DOR Duration of Response, mOS Median Overall Survival, PFS Progression-Free Survival, LBCB Large B-Cell Lymphoma, BCP-ALL B-Cell Precursor Acute Lymphoblastic Leukemia, HCL Hairy Cell Leukemia, TNBC Triple-Negative Breast Cancer, EGFR Epidermal Growth Factor Receptor, BCMA B-Cell Maturation Antigen, MMAE Monomethyl auristatin E, TROP-2 Trophoblast Cell Surface Antigen 2, TF Tissue Factor, HER2 Human Epidermal Growth Factor Receptor 2, FRα Folate Receptor Alpha. Data accessed on 24th March 2024